Last €140.63 EUR
Change Today +1.32 / 0.95%
Volume 35.0
J7Z On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 2:04 PM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

jazz pharmaceuticals plc (J7Z) Snapshot

Open
€139.54
Previous Close
€139.31
Day High
€140.63
Day Low
€139.41
52 Week High
11/5/14 - €140.68
52 Week Low
12/16/13 - €79.82
Market Cap
8.5B
Average Volume 10 Days
18.8
EPS TTM
--
Shares Outstanding
60.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for JAZZ PHARMACEUTICALS PLC (J7Z)

jazz pharmaceuticals plc (J7Z) Related Businessweek News

No Related Businessweek News Found

jazz pharmaceuticals plc (J7Z) Details

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients. In addition, it offers products in the areas of hematology and oncology drugs, such as Asparec, which is in Phase I clinical trial for the treatment of patients with ALL with E.coli asparaginase hypersensitivity; Defibrotide for the treatment of severe VOD; and Leukotac, an anti-CD25 monoclonal antibody that is in Phase III clinical trials and is intended for the treatment of steroid-refractory acute GvHD. The company is headquartered in Dublin, Ireland.

870 Employees
Last Reported Date: 11/4/14

jazz pharmaceuticals plc (J7Z) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: $771.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $419.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $547.0K
Executive Vice President and General Counsel
Total Annual Compensation: $536.0K
Consultant
Total Annual Compensation: $472.7K
Compensation as of Fiscal Year 2013.

jazz pharmaceuticals plc (J7Z) Key Developments

Jazz Pharmaceuticals Public Limited Company Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for 2014

Jazz Pharmaceuticals Public Limited Company announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $306,584,000 against $232,160,000 a year ago. Income from operations was $58,036,000 against $100,560,000 a year ago. Income before income tax provision of $49,989,000 against $93,744,000 a year ago. Net income attributable to Jazz Pharmaceuticals plc was $25,766,000 or $0.41 per share diluted against $75,409,000 or $1.23 per share diluted a year ago. Total revenues increased 32% was driven primarily by net product sales of Xyrem (sodium oxybate) oral solution, Erwinaze /Erwinase (asparaginase Erwinia chrysanthemi) and Defitelio (defibrotide). For the nine months, the company reported total revenues of $844,733,000 against $636,649,000 a year ago. Income from operations was $65,668,000 against $245,813,000 a year ago. Income before income tax provision of $36,313,000 against $220,593,000 a year ago. Net loss attributable to Jazz Pharmaceuticals plc was $23,225,000 or $0.39 per share diluted against net income attributable to Jazz Pharmaceuticals plc of $161,019,000 or $2.62 per share diluted a year ago. Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc was $374,444,000 or $5.99 per share diluted against $282,131,000 or $4.59 per share diluted a year ago. Non-GAAP income before income tax provision was $462,979,000 compared with $344,903,000 for the same period last year. For the full year, the company expects revenue to range $1,150 million to $1,170 million. Total net product sales to range $1,142 million to $1,160 million. Adjusted gross margin to range 91% to 92%. Adjusted R&D expenses to range $65 million to $75 million. GAAP net income attributable to Jazz Pharmaceuticals plc per diluted share to range $0.73-$1.05. Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc per diluted share to range $8.20-$8.35.

Jazz Pharmaceuticals Public Limited Company to Report Q3, 2014 Results on Nov 04, 2014

Jazz Pharmaceuticals Public Limited Company announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 04, 2014

Jazz Pharmaceuticals Public Limited Company, Q3 2014 Earnings Call, Nov 04, 2014

Jazz Pharmaceuticals Public Limited Company, Q3 2014 Earnings Call, Nov 04, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
J7Z:GR €140.63 EUR +1.32

J7Z Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $39.18 USD +1.14
Alkermes PLC $55.01 USD +0.84
BioMarin Pharmaceutical Inc $89.38 USD -0.07
Sagent Pharmaceuticals Inc $28.82 USD +0.42
Salix Pharmaceuticals Ltd $103.25 USD +0.91
View Industry Companies
 

Industry Analysis

J7Z

Industry Average

Valuation J7Z Industry Range
Price/Earnings 100.0x
Price/Sales 9.5x
Price/Book 7.7x
Price/Cash Flow 70.0x
TEV/Sales 7.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit www.jazzpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.